Clone REAL687 is an antibody fragment derived from the full CD99 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL687 recognizes the human CD99 antigen, a 32 kDa type I single chain transmembrane sialoglycoprotein which is also known as E2 antigen or MIC2. The expression level of CD99 is particularly high in thymocytes, T cells, T cell leukemias and lymphomas, subsets of mature plasma cells in the medullary cord of reactive lymph nodes, pancreatic islet cells, granulosa cells of the ovary, Sertoli cells of the testes, but absent on granulocytes. It is involved in T cell–adhesion processes and in spontaneous rosette formation with erythrocytes. CD99 plays a role in a late step of leukocyte extravasation helping leukocytes to overcome the endothelial basement membrane and it acts at the same site as, but independently of, PECAM1. It also have the ability to rearrange the actin cytoskeleton and act as an oncosuppressor in osteosarcoma.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.